Tenax Therapeutics, Inc. (TENX)

Tenax Therapeutics is working on a single class of heart medicines derived from a compound that doctors have used successfully for decades outside the United States. The company takes an old drug—intravenous levosimendan, a calcium sensitizer and potassium channel opener developed by a Finnish company—and is remaking it in new forms, most importantly as an oral pill, to treat a specific heart problem that has few good options.

What problem does Tenax solve?

The target condition is pulmonary hypertension with heart failure and preserved ejection fraction. Call it PH-HFpEF. That’s a long name for something specific: patients whose hearts pump normally (the ventricle ejects a healthy fraction of blood with each beat) but whose hearts are stiff, do not relax well, and cannot fill properly with blood. That stiffness, over time, causes pressure to back up in the blood vessels feeding the lungs. High lung pressure is pulmonary hypertension. High lung pressure in the setting of a stiff heart is the particular form Tenax targets.

This is not an invented disease. It is real, growing more common as the population ages, and it causes exercise limitation, shortness of breath, and reduced life expectancy. Existing treatments for pulmonary hypertension work reasonably well when the underlying problem is the lungs or specific heart chambers; they work less well in PH-HFpEF because the core problem is diastolic dysfunction—a heart that does not relax. The drug landscape here is thin. Tenax believes levosimendan, by lowering the pressure in the pulmonary circulation and improving the heart’s ability to relax and fill, could meaningfully help these patients.

How levosimendan works

Levosimendan is a dual-action drug. It sensitizes the heart muscle to calcium, making the heart contract harder and more efficiently without increasing oxygen demand (that matters in a failing heart, which is energy-starved). It also opens potassium channels in blood vessel walls, causing vasodilation—the veins relax, pressure drops, and the load on the failing heart eases. In Europe, the Middle East, and Asia, intravenous levosimendan has been approved and used for decades in acutely decompensated heart failure, with a track record of safety.

Tenax does not own levosimendan. A Finnish pharmaceutical company, Orion, discovered and developed it. Tenax licensed the North American rights from Orion to develop and commercialize three formulations: intravenous (TNX-101), subcutaneous (TNX-102), and oral (TNX-103). The oral form is the big prize. An oral drug is easier to take, cheaper to manufacture, and suited to chronic outpatient use—a potential blockbuster modality, if it works. An IV drug is for acute hospital settings; an oral drug is for home, lifelong treatment.

The path Tenax is taking

In November 2023, Tenax received FDA clearance to test TNX-103 (oral levosimendan) in humans under an Investigational New Drug application. That clearance meant the company could move into Phase 3—late-stage efficacy trials, the step right before a drug either succeeds and gets approved or fails and is abandoned.

Tenax initiated the LEVEL study in early 2024, enrolling patients with PH-HFpEF into a randomized trial comparing TNX-103 to placebo. The trial’s primary endpoint is six-minute walking distance—a measure of exercise capacity that is simple, objective, and clinically meaningful. Patients take the drug or placebo for weeks or months, walk as far as they can in six minutes, and researchers measure how much farther (or whether) the drug group went compared to placebo. A statistically meaningful improvement in that endpoint, if seen, would be strong evidence of drug efficacy.

Tenax also announced a second Phase 3 trial, LEVEL-2, also focused on PH-HFpEF. Two trials in the same indication is standard in late-stage development; if one is positive, regulators usually want to see the result confirmed in an independent trial before granting approval.

Where Tenax sits in the drug landscape

Tenax is a small, clinical-stage company entirely focused on this single drug class. It has no approved products and no revenue. All the money that flows in comes from equity investors and, potentially, partnering deals. All the money that flows out goes to pay scientists, conduct trials, and stay alive. The company burns cash with each passing quarter.

The risk is not subtle: the trials could fail. The drug could show no advantage over placebo. The patient population could prove harder to recruit than expected. Safety problems could emerge in the trial data. Any of these outcomes would be bad for shareholders and would end the company’s prospects (unless a larger pharma company wanted to acquire the asset for a salvage price).

The opportunity is equally stark: if the trials succeed, Tenax will have demonstrated that oral levosimendan works in a large, underserved patient population with few effective treatments. A successful Phase 3 would attract attention from major pharmaceutical companies, any of which could acquire Tenax wholesale, license the drug, or partner for development and commercialization. The acquirer would then scale manufacturing, marketing, and sales—turning a small biotech lab experiment into a real medicine on pharmacy shelves, available to tens of thousands of patients.

Capital and partnerships

Tenax is funded by equity investors and strategic partnerships. The Orion license is one such partnership: Tenax pays milestones and royalties to Orion for the rights to develop and sell the drug in North America. Larger pharma companies have shown interest in the program; partnerships or acquisitions are common in late-stage biotech, especially when a small company has proven the science but lacks the manufacturing and commercial scale to launch a drug.

The company’s balance sheet and cash runway are disclosed in SEC filings (10-K annual reports and 10-Q quarterly updates). Clinical-trial progress is disclosed in press releases and on clinicaltrials.gov, the publicly maintained registry of all human drug trials. These sources are the primary way to monitor Tenax and judge whether the LEVEL and LEVEL-2 trials are advancing as promised.

The bottom line

Tenax is a bet on the proposition that a repurposed, well-studied drug—levosimendan, used successfully in other countries for two decades—can be reformulated as an oral tablet and proven effective in a heart disease where today’s treatments fall short. The science is credible; the unmet need is real; the risk is clinical and regulatory. The company has reached a pivotal moment: Phase 3 trials are underway. Either the data will support approval, creating a valuable asset and a likely acquisition target, or the trials will disappoint, and Tenax’s prospects will dim considerably. That binary outcome—success or major setback—is inherent in late-stage drug development and is why biotech investors accept such high risk in pursuit of occasional very large returns.